LGVN earnings analysis
What we found in LGVN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 2026 revenue was $316,000, down 20.6% sequentially and unchanged year over year, while gross margin fell to 46.2% and diluted EPS worsened to $(0.33). Operating margin remained deeply negative at negative 1,707.9%, and free cash flow was negative $4.0 million. The principal concern is liquidity: $10.1 million of cash is expected to fund operations only into Q4 2026, with additional financing needed and ATM access constrained by a $0.80 share-price condition. Nasdaq compliance was improved through a 4-member independent Audit Committee, but the separate $1.00 bid-price deficiency remains unresolved until the September 21, 2026 compliance date.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue declined sequentially
- Revenue was $316,000, down 20.6% from $398,000 in Q1 2026 and flat versus $316,000 in Q2 2025.
- Gross margin compressed
- Gross margin was 46.2%, down from 66.3% in Q1 2026 and 72.2% in Q2 2025, a sequential decline of 20.1 percentage points.
- Quarterly loss widened
- Diluted EPS was $(0.33), versus $(0.19) in Q1 2026 and $(0.33) in Q2 2025; the sequential loss widened by $0.14 per share.
- Operating losses remain substantial
- Operating margin was negative 1,707.9%, deteriorating from negative 1,199.8% in Q1 2026 and negative 1,707.9% in Q2 2025.
- Audit committee compliance remedied
- The company stated that its Audit Committee was reconstituted with 4 independent members after the election of 3 new directors on July 1, 2026; 1 member qualifies as an audit committee financial expert.
- Near-term cash runway identified
- Management reported cash and cash equivalents of $10.1 million at June 30, 2026, which it expects to fund operations into the fourth quarter of 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Funding runway remains limited
- Management expects cash of $10.1 million to fund operations only into Q4 2026 and states that additional funding will be required to advance programs. The ATM facility permits sales of up to $10.7 million, but use is restricted unless the stock trades above $0.80 through September 7, 2026.
- Nasdaq bid-price deficiency
- The company must regain Nasdaq's $1.00 minimum bid-price requirement by September 21, 2026. If it fails, Nasdaq will begin delisting procedures; a closing bid price of $0.10 or less for 10 consecutive trading days before that date could lead to immediate suspension and delisting proceedings.
- R&D spending raises capital needs
- Management expects increased spending for clinical development, BLA-enabling work and potential commercialization, while stating that additional financing may be needed through capital raises, non-dilutive funding and partnering. Failure to obtain financing could require materially revising the operating plan or delaying, scaling back or discontinuing programs.
- Persistent cash burn
- Free cash flow was negative $4.0 million in the quarter, following negative $5.0 million in Q1 2026 and negative $4.0 million in Q2 2025, indicating continued cash consumption despite $316,000 of revenue.
- ATM access is constrained
- The company states that the ATM facility was under a standstill until June 9, 2026 and remains subject to the $0.80 trading-price restriction through September 7, 2026, limiting a potential source of liquidity during the near-term runway.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.33
- Gross margin
- 46.2%
- Operating margin
- -1707.9%
What they said about what is next.
No explicit numeric revenue or EPS guidance was provided. Management stated that cash and cash equivalents of $10.1 million are expected to fund operations into the fourth quarter of 2026, while spending is expected to increase for clinical, BLA-enabling and commercialization activities.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Longeveron reported a slight increase in revenue for Q1 2026, totaling $400,000, driven by a 46% increase in clinical trial revenues. However, the company continued to face significant losses, with a net loss of $4.7…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LGVN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever